Testing BBB transport of neuropharmaceuticals

cOFM samples all substances in the brain with an intact BBB

The blood brain barrier (BBB) protects the brain but it also impedes the transport of neuropharmaceuticals to the brain. cOFM (cerebral open flow microperfusion) allows sampling in numerous brain regions with an intact BBB. cOFM studies provide data for drug development as well as unique insights into brain metabolism and signaling.

cOFM features


  • Monitoring of substance transport across the intact BBB
  • Monitoring of neuronal biomarkers e.g. leptin, tau-protein with no limitation regarding substance size and lipophilicity
  • Monitoring of BBB function and permeability changes



  • Time-resolved substance concentration monitoring in the brain
  • Sampling in different brain areas in parallel and direct comparison between CSF and brain ISF
  • Use in various animal models from mouse/rat to primate

Webinar: Cerebral Open Flow Microperfusion (cOFM) for in vivo Cerebral Fluid Sampling – Comparison of cOFM and Microdialysis

cOFM Webinar: Cerebral Open Flow Microperfusion (cOFM) for in vivo Cerebral Fluid Sampling – Comparison of cOFM and Microdialysis

Join Dr. Joanna Hummer and Dr. Florie Le Prieult as they share insights into cOFM's use and utility in the broader neuroscience field and specifically for the development of drugs for neurodegenerative diseases on October 14th 2021.

About cOFM

cOFM is a unique tool to investigate brain pharmacokinetics (PK) and pharmacodynamics (PD) with an intact BBB. Implantation of a probe into the brain region of interest causes rupture of blood vessels and local destruction of the BBB. When performing cOFM experiments, the BBB is allowed to heal and to re-establish for 2 weeks after cOFM probe implantation, and cOFM sampling is then performed with intact BBB. During sampling, the cOFM probe is continuously perfused with a physiological fluid (perfusate). The perfusate exchanges molecules with the cerebral interstitial fluid (ISF) along the exchange area at the tip of the cOFM probe, resulting in diluted and also unfiltered cerebral ISF samples, as no membrane is involved. The collected cerebral ISF samples contain all molecules present in the brain tissue without restriction due to size or inherent chemical properties including drugs, proteins and antibodies.

The most specific feature of cOFM is its capability of sampling cerebral ISF with intact BBB which allows assessment of the ability of the drug to cross the BBB. Further, longitudinal sampling for up to several weeks can be performed, yielding time-resolved, high-quality data that deliver PK and PD concentration profiles.


Reference project

PK of nanoformulated cancer drugs in the brain

cOFM was successfully used to measure substance transport enhanced by nanocarriers across the blood-brain barrier

Read more